Table 2.

Univariate log-rank analysis for important clinicopathological variables and CHD4 expression. In the multivariate regression analysis, CHD4 over-expression was an independent factor of poor prognosis for MeFS (p = 0.002) after adjustment.

Parameter		No. of Case	DSS		LRFS		MeFS
			No. of Event	p-Value	No. of Event	p-Value	No. of Event	p-Value
Gender	Male	108	20	0.6027	5	0.3096	14	0.1047
	Female	64	11		17		15
Age	<70	106	19	0.7158	14	0.9630	18	0.9520
	≥70	66	12		8		11
Pre-Tx tumor status (Pre-T)	T1–T2	81	10	0.0484 *	7	0.0836	10	0.1288
	T3–T4	91	21		15		19
Pre-Tx nodal status (Pre-N)	N0	125	19	0.0059 *	12	0.0025 *	18	0.0866
	N1–N2	47	21		10		11
Post-Tx tumor status (Post-T)	T1–T2	86	7	0.0014 *	5	0.0056 *	8	0.0123 *
	T3–T4	86	24		17		21
Post-Tx nodal status (Post-N)	N0	123	21	0.4654	15	0.6267	20	0.8403
	N1–N2	49	10		7		9
Vascular invasion	Absent	157	25	0.0123 *	17	0.0023 *	26	0.7236
	Present	15	6		5		3
Perineural invasion	Absent	167	29	0.0994	20	0.0083 *	28	0.8157
	Present	5	2		2		1
Tumor regression grade	Grade 0–1	37	13	0.0037 *	10	0.0021 *	14	0.0008 *
	Grade 2–3	118	17		12		14
	Grade 4	17	1		0		1
Down stage after CCRT	Non-Significant	150	29	0.2348	20	0.5234	28	0.1291
	Significant (≥2)	22	2		2		1
CHD4 expression	Low Exp.	89	11	0.0373 *	15	0.8949	5	<0.0001 *
	High Exp.	83	20		12		26

*, statistically significant.